ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Lilly's galcanezumab significantly reduces number of migraine headache days
June 14, 2017Eli Lilly has announced positive results from three Phase III studies of galcanezumab, an investigational treatment for the prevention of episodic and chronic migraine, including late-breaking data on several key secondary endpoints for galcanezumab compa
Pharma Sources Insight January 2025
